RESUMEN
INTRODUCTION: Homeopathic remedies are highly diluted formulations without proven clinical benefits, traditionally believed not to cause adverse events. Nonetheless, published literature reveals severe local and non-liver-related systemic side effects. We present the first series on homeopathy-related severe drug-induced liver injury (DILI) from a single center. METHODS: A retrospective review of records from January 2019 to February 2022 identified 9 patients with liver injury attributed to homeopathic formulations. Competing causes were comprehensively excluded. Chemical analysis was performed on retrieved formulations using triple quadrupole gas chromatography-mass spectrometry and inductively coupled plasma atomic emission spectroscopy. RESULTS: Males predominated with a median age of 54 years. The most typical clinical presentation was acute hepatitis, followed by acute on chronic liver failure. All patients developed jaundice, and ascites were notable in one-third of the patients. Five patients had underlying chronic liver disease. COVID-19 prevention was the most common indication for homeopathic use. Probable DILI was seen in 77.8%, and hepatocellular injury predominated (66.7%). Four (44.4%) patients died (3 with chronic liver disease) at a median follow-up of 194 days. Liver histopathology showed necrosis, portal and lobular neutrophilic inflammation, and eosinophilic infiltration with cholestasis. A total of 29 remedies were consumed between 9 patients, and 15 formulations were analyzed. Toxicology revealed industrial solvents, corticosteroids, antibiotics, sedatives, synthetic opioids, heavy metals, and toxic phyto-compounds, even in 'supposed' ultra-dilute formulations. CONCLUSION: Homeopathic remedies potentially result in severe liver injury, leading to death in those with underlying liver disease. The use of mother tinctures, insufficient dilution, poor manufacturing practices, adulteration and contamination, and the presence of direct hepatotoxic herbals were the reasons for toxicity. Physicians, the public, and patients must realize that Homeopathic drugs are not 'gentle placebos.'
Asunto(s)
COVID-19 , Enfermedad Hepática Inducida por Sustancias y Drogas , Homeopatía , Materia Medica , Masculino , Humanos , Persona de Mediana Edad , Materia Medica/efectos adversos , Homeopatía/efectos adversos , Homeopatía/métodos , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Enfermedad Hepática Inducida por Sustancias y Drogas/epidemiología , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , India/epidemiologíaRESUMEN
BACKGROUND: Alternative medicine is used instead of conventional therapy. Some patients use it in parallel with conventional medicine. OBJECTIVE: Narrative compilation of the evidence on alternative medicine in the (uro)oncological context. MATERIALS AND METHODS: A selective literature search in MEDLINE via PubMed was performed. RESULTS: The data on 3bromopyruvate, Miracle Mineral Supplement (MMS), insulin-potentiated therapy, base therapy, hyperthermia, Artemisia annua, amygdalin (vitamin B17), Amanita therapy, homeopathy, apitherapy, dendritic cells, galavit, Germanic new medicine, and spiritual healing show either no or little clinical evidence of efficacy or clearly exhibit a negative benefit-risk profile. CONCLUSIONS: Alternative medicine is pseudo-medicine that may have a positive effect on mental well-being in the short term, but is mostly associated with disadvantages for the patient in the long term.
Asunto(s)
Artemisia annua , Terapias Complementarias , Homeopatía , Humanos , Homeopatía/efectos adversos , Salud Mental , Neoplasias Urogenitales/terapiaRESUMEN
PURPOSE: In this systematic review we included clinical studies from 1800 until 2020 to evaluate evidence of the effectiveness of homeopathy on physical and mental conditions in patients during oncological treatment. METHOD: In February 2021 a systematic search was conducted searching five electronic databases (Embase, Cochrane, PsychInfo, CINAHL and Medline) to find studies concerning use, effectiveness and potential harm of homeopathy in cancer patients. RESULTS: From all 1352 search results, 18 studies with 2016 patients were included in this SR. The patients treated with homeopathy were mainly diagnosed with breast cancer. The therapy concepts include single and combination homeopathic remedies (used systemically or as mouth rinses) of various dilutions. Outcomes assessed were the influence on toxicity of cancer treatment (mostly hot flashes and menopausal symptoms), time to drain removal in breast cancer patients after mastectomy, survival, quality of life, global health and subjective well-being, anxiety and depression as well as safety and tolerance. The included studies reported heterogeneous results: some studies described significant differences in quality of life or toxicity of cancer treatment favouring homeopathy, whereas others did not find an effect or reported significant differences to the disadvantage of homeopathy or side effects caused by homeopathy. The majority of the studies have a low methodological quality. CONCLUSIONS: For homeopathy, there is neither a scientifically based hypothesis of its mode of action nor conclusive evidence from clinical studies in cancer care.
Asunto(s)
Neoplasias de la Mama , Homeopatía , Humanos , Femenino , Homeopatía/efectos adversos , Homeopatía/métodos , Neoplasias de la Mama/terapia , Neoplasias de la Mama/etiología , Calidad de Vida , Mastectomía , AnsiedadRESUMEN
BACKGROUND: Complementary therapy in oncology aims to help patients better cope with the illness and side effects (SEs) of cancer treatments that affect their quality of life (QOL). This study aimed to assess the benefits of homeopathic treatment on the health-related QOL (HRQOL) of patients with non-metastatic breast cancer (BC) prescribed in postsurgical complementary therapy. PATIENTS AND METHODS: An extraction from the French nationwide healthcare database targeted all patients who underwent mastectomy for newly diagnosed BC between 2012 and 2013. HRQOL was proxied by the quantity of medication used to palliate the SEs of cancer treatments. RESULTS: A total of 98,009 patients were included (mean age: 61 ± 13 years). Homeopathy was used in 11%, 26%, and 22% of patients respectively during the 7 to 12 months before surgery, the 6 months before, and 6 months after. Thereafter, the use remained stable at 15% for 4 years. Six months after surgery, there was a significant overall decrease (RR = 0.88, confidence interval (CI)95 = 0.87-0.89) in the dispensing of medication associated with SEs in patients treated with ≥ 3 dispensing of homeopathy compared to none. The decrease appeared to be greater for immunostimulants (RR = 0.79, (CI)95 = 0.74-0.84), corticosteroids (RR = 0.82, (CI)95 = 0.79-0.85), and antidiarrheals (RR = 0.83, (CI)95 = 0.77-0.88). CONCLUSION: The study showed an increasing use of homeopathy in patients with BC following diagnosis. This use was maintained after surgery and seemed to play a role in helping patients to better tolerate the SEs of cancer treatments.
Asunto(s)
Neoplasias de la Mama , Homeopatía , Humanos , Persona de Mediana Edad , Anciano , Femenino , Homeopatía/efectos adversos , Neoplasias de la Mama/terapia , Neoplasias de la Mama/etiología , Calidad de Vida , Estudios Retrospectivos , Mastectomía/efectos adversos , Atención a la SaludRESUMEN
Context: Breast abscess is the most common complication of acute bacterial mastitis usually referred to as pyogenic mastitis. It is usually encountered during lactation due to an infection with Staphylococcus aureus and streptococcal bacteria. These bacteria produce a severe inflammatory reaction leading to pus formation which is mainly treated by ultrasound-guided drainage or fine needle aspirations. We find that in this condition homoeopathic treatment can play an important role as it avoids such surgical procedures and helps in healing in a most gentle and rapid way. We report a successful single case study that opens up opportunities to take up more such cases to strengthen the results of this report. Case summary: A 23-year-old lactating mother came with complaints of pain and swelling with a collection of pus in the breast region and decreased breast milk secretion. Individualised homoeopathic medicine Silicea 200C was given to hasten suppuration and Belladonna 200C to treat inflammation.Thus, this case shows us how only few doses of medicine may be quickly helpful in managing a case of breast abscess without the need of any surgical procedures.
Asunto(s)
Enfermedades de la Mama , Homeopatía , Mastitis , Femenino , Humanos , Adulto Joven , Adulto , Enfermedades de la Mama/terapia , Enfermedades de la Mama/complicaciones , Absceso/etiología , Absceso/microbiología , Lactancia , Homeopatía/efectos adversos , Mastitis/etiología , Mastitis/microbiología , Supuración/complicacionesRESUMEN
Introduction: Alopecia areata is a dermatological disorder characterized by hair loss. The exact cause is still unknown but is linked with an autoimmune disease. No efficient treatment is known though many studies have been conducted, yet the optimal treatment is not known. Methods: The case was treated in the Dermatological Department at Dr. D. Y. Patil Homoeopathic Medical College and Research Centre. A 42-year-old female patient with alopecia areata was treated with individualized homoeopathic medicine (iHOM) between 2nd May 2019 and 16th January 2020. During the follow-up visits, the outcome was assessed. To evaluate whether the changes were due to homoeopathic medicine, an assessment using the Modified Naranjo criteria was performed. Results: Over an observational period of eight-months, positive results from iHOM medicine were seen. This treatment can be used by the physicians in the treatment of alopecia areata as a complementary health practice. Conclusion: Considering the multi-factorial aetiology of alopecia areata, iHOM along with local treatment may be effective in treating alopecia areata.
Asunto(s)
Alopecia Areata , Enfermedades Autoinmunes , Homeopatía , Materia Medica , Femenino , Humanos , Adulto , Alopecia Areata/tratamiento farmacológico , Alopecia Areata/etiología , Homeopatía/efectos adversos , Enfermedades Autoinmunes/complicaciones , Materia Medica/uso terapéuticoRESUMEN
BACKGROUND: Acute respiratory tract infections (ARTIs) are common and may lead to complications. Most children experience between three and six ARTIs annually. Although most infections are self-limiting, symptoms can be distressing. Many treatments are used to control symptoms and shorten illness duration. Most treatments have minimal benefit and may lead to adverse events. Oral homeopathic medicinal products could play a role in childhood ARTI management if evidence for their effectiveness is established. This is an update of a review first published in 2018. OBJECTIVES: To assess the effectiveness and safety of oral homeopathic medicinal products compared with placebo or conventional therapy to prevent and treat ARTIs in children. SEARCH METHODS: We searched CENTRAL (2022, Issue 3), including the Cochrane Acute Respiratory Infections Specialised Register, MEDLINE (1946 to 16 March 2022), Embase (2010 to 16 March 2022), CINAHL (1981 to 16 March 2022), AMED (1985 to 16 March 2022), CAMbase (searched 16 March 2022), and British Homeopathic Library (searched 26 June 2013 - no longer operating). We also searched the WHO ICTRP and ClinicalTrials.gov (16 March 2022), checked references, and contacted study authors to identify additional studies. SELECTION CRITERIA: We included double-blind randomised controlled trials (RCTs) or double-blind cluster-RCTs comparing oral homeopathy medicinal products with identical placebo or self-selected conventional treatments to prevent or treat ARTIs in children aged 0 to 16 years. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: In this 2022 update, we identified three new RCTs involving 251 children, for a total of 11 included RCTs with 1813 children receiving oral homeopathic medicinal products or a control treatment (placebo or conventional treatment) for ARTIs. All studies focused on upper respiratory tract infections (URTIs), with only one study including some lower respiratory tract infections (LRTIs). Six treatment studies examined the effect on URTI recovery, and five studies investigated the effect on preventing URTIs after one to four months of treatment. Two treatment and three prevention studies involved homeopaths individualising treatment. The other studies used predetermined, non-individualised treatments. All studies involved highly diluted homeopathic medicinal products, with dilutions ranging from 1 x 10-4 to 1 x 10-200. We identified several limitations to the included studies, in particular methodological inconsistencies and high attrition rates, failure to conduct intention-to-treat analysis, selective reporting, and apparent protocol deviations. We assessed three studies as at high risk of bias in at least one domain, and many studies had additional domains with unclear risk of bias. Four studies received funding from homeopathy manufacturers; one study support from a non-government organisation; two studies government support; one study was co-sponsored by a university; and three studies did not report funding support. Methodological inconsistencies and significant clinical and statistical heterogeneity precluded robust quantitative meta-analysis. Only four outcomes were common to more than one study and could be combined for analysis. Odds ratios (OR) were generally small with wide confidence intervals (CI), and the contributing studies found conflicting effects, so there was little certainty that the efficacy of the intervention could be ascertained. All studies assessed as at low risk of bias showed no benefit from oral homeopathic medicinal products, whilst trials at unclear or high risk of bias reported beneficial effects. For the comparison of individualised homeopathy versus placebo or usual care for the prevention of ARTIs, two trials reported on disease severity; due to heterogeneity the data were not combined, but neither study demonstrated a clinically significant difference. We combined data from two trials for the outcome need for antibiotics (OR 0.79, 95% CI 0.35 to 1.76; low-certainty evidence). For the comparison of non-individualised homeopathy versus placebo or usual care for the prevention of ARTIs, only the outcome recurrence of ARTI was reported by more than one trial; data from three studies were combined for this outcome (OR 0.60, 95% CI 0.21 to 1.72; low-certainty evidence). For the comparison of both individualised and non-individualised homeopathy versus placebo or usual care for the treatment of ARTIs, two studies provided data on short-term cure (OR 1.31, 95% CI 0.09 to 19.54) and long-term cure (OR 1.01, 95% CI 0.10 to 9.96; very low-certainty evidence). The studies demonstrated an opposite direction of effect for both outcomes. Six studies reported on disease severity but were not combined as they used different scoring systems and scales. Three studies reported adverse events (OR 0.79, 95% CI 0.16 to 4.03; low-certainty evidence). AUTHORS' CONCLUSIONS: Pooling of five prevention and six treatment studies did not show any consistent benefit of homeopathic medicinal products compared to placebo on ARTI recurrence or cure rates in children. We assessed the certainty of the evidence as low to very low for the majority of outcomes. We found no evidence to support the efficacy of homeopathic medicinal products for ARTIs in children. Adverse events were poorly reported, and we could not draw conclusions regarding safety.
Asunto(s)
Homeopatía , Infecciones del Sistema Respiratorio , Niño , Humanos , Antibacterianos/uso terapéutico , Homeopatía/efectos adversos , Análisis de Intención de Tratar , Ensayos Clínicos Controlados Aleatorios como Asunto , Infecciones del Sistema Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/tratamiento farmacológicoRESUMEN
Context: Cervical spondylosis (CS) is a chronic degenerative condition that presents with chronic neck pain and stiffness with radiation of pain to the occiput or upper limbs and a sensation of numbness or tingling. Conservative treatment only provides short term relief. Objective: This case was undertaken to evaluate the efficacy of individualised homoeopathy in the management of CS. Methods: A 39-year-old female patient was treated in the outpatient dept at Dr. D. Y. Patil homoeopathic medical college and research centre with the complaint of neck pain with stiffness. Radiological findings revealed the diagnosis of cervical spondylosis. Individualised homoeopathic medicine was selected after detailed case taking. 'Modified naranjo criteria' were used to assess the effect of homoeopathic medicine. Result: Homoeopathic medicine silicea terra was prescribed and found to be effective in this case. Conclusion: Further studies can be undertaken to assess the effectiveness of individualised homoeopathic medicine in the management of cervical spondylosis.
Asunto(s)
Homeopatía , Materia Medica , Espondilosis , Adulto , Vértebras Cervicales/diagnóstico por imagen , Femenino , Homeopatía/efectos adversos , Humanos , Dolor de Cuello/diagnóstico , Dolor de Cuello/etiología , Dolor de Cuello/terapia , Espondilosis/complicaciones , Espondilosis/diagnóstico por imagen , Espondilosis/terapiaRESUMEN
BACKGROUND: Almost all health care interventions have the potential to be associated with risk to patient safety. Different terminologies are used to define treatment induced risk to patient safety and a common definition is the term adverse effect. Beyond the concept of adverse effect and specific to homeopathy is the concept of homeopathic aggravation. Homeopathic aggravation describes a transient worsening of the patients' symptoms, which is not understood as an adverse effect. In order to ensure patient safety within a homeopathic treatment setting, it is important to identify adverse effects, as well as homeopathic aggravations, even though it may be challenging to distinguish between these two concepts. To date there is an obvious lack of systematic information on how adverse effects and homeopathic aggravations are reported in studies. This systematic review and meta-analysis focuses on observational studies, as a substantial amount of the research base for homeopathy are observational. METHOD: Eight electronic databases, central webpages and journals were searched for eligible studies. The searches were limited from the year 1995 to January 2020. The filters used were observational studies, human, English and German language. Adverse effects and homeopathic aggravations were identified and graded according to The Common Terminology Criteria for Adverse Effects (CTCAE). Meta-analysis was performed separately for adverse effects and homeopathic aggravations. RESULTS: A total of 1,169 studies were identified, 41 were included in this review. Eighteen studies were included in a meta-analysis that made an overall comparison between homeopathy and control (conventional medicine and herbs). Eighty-seven percent (n = 35) of the studies reported adverse effects. They were graded as CTCAE 1, 2 or 3 and equally distributed between the intervention and control groups. Homeopathic aggravations were reported in 22,5% (n = 9) of the studies and graded as CTCAE 1 or 2. The frequency of adverse effects for control versus homeopathy was statistically significant (P < 0.0001). Analysis of sub-groups indicated that, compared to homeopathy, the number of adverse effects was significantly higher for conventional medicine (P = 0.0001), as well as other complementary therapies (P = 0.05). CONCLUSION: Adverse effects of homeopathic remedies are consistently reported in observational studies, while homeopathic aggravations are less documented. This meta-analysis revealed that the proportion of patients experiencing adverse effects was significantly higher when receiving conventional medicine and herbs, compared to patients receiving homeopathy. Nonetheless, the development and implementation of a standardized reporting system of adverse effects in homeopathic studies is warranted in order to facilitate future risk assessments.
Asunto(s)
Homeopatía , Empleos en Salud , Homeopatía/efectos adversos , Humanos , Estudios Observacionales como Asunto , Medición de RiesgoRESUMEN
OBJECTIVES: To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care. TRIAL DESIGN: A randomized, two-armed (1:1), parallel, placebo-controlled, double-blind, clinical trial is being performed to test the following hypotheses: H0: homeopathic medicines = placebo (null hypothesis) vs. H1: homeopathic medicines ≠ placebo (alternative hypothesis) for mild cases of COVID-19 in Primary Care. PARTICIPANTS: Setting: Primary Care of São Carlos - São Paulo - Brazil. One hundred participants aged 18 years or older, with Influenza-like symptoms and a positive RT-PCR for SARS-CoV-2. Willingness to give informed consent and to comply with the study procedures is also required. Exclusion criterium: severe acute respiratory syndrome. INTERVENTION AND COMPARATOR: Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30% and dispensed in a 30 ml bottle. Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle. Posology: one drop taken orally every 4 hours (6 doses/day) while there is fever, cough, tiredness, or pain (headache, sore throat, muscle aches, chest pain, etc.) followed by one drop every 6 hours (4 doses/day) until the fourteenth day of use. The bottle of study medication should be submitted to 10 vigorous shakes (succussions) before each dose. Posology may be changed by telemedicine, with no break in blinding. Study medication should be maintained during home isolation. According to the Primary Care protocol, the home isolation period lasts until the 10th day after the appearance of the first symptom, or up to 72 hours without symptoms. MAIN OUTCOMES: The primary endpoint will be time to recovery, defined as the number of days elapsed before all COVID-19 Influenza-like symptoms are recorded as mild or absent during home isolation period. Secondary measures are recovery time for each COVID-19 symptom; score of the scale created for the study (COVID-Simile Scale); medicines used during follow-up; number of days of follow-up; number of visits to emergency services; number of hospitalizations; other symptoms and Adverse Events during home isolation period. RANDOMISATION: The study Statistician generated a block randomization list, using a 1:1 ratio of the two groups (denoted as A and B) and a web-based tool ( http://www.random.org/lists ). BLINDING (MASKING): The clinical investigators, the statistician, the Primary Care teams, the study collaborators, and the participants will remain blinded from the identity of the two treatment groups until the end of the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): One hundred participants are planned to be randomized (1:1) to placebo (50) or homeopathy (50). TRIAL STATUS: Protocol version/date May 21, 2020. Recruitment is ongoing. First participant was recruited/included on June 29,2020. Due to recruitment adaptations to Primary Care changes, the authors anticipate the trial will finish recruiting on April 10, 2021. TRIAL REGISTRATION: COVID-Simile Study was registered at the University Hospital Medical Information Network (UMIN - https://www.umin.ac.jp/ctr/index.htm ) on June 1st, 2020, and the trial start date was June 15, 2020. Unique ID: UMIN000040602. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Asunto(s)
COVID-19/terapia , Homeopatía/métodos , Materia Medica/administración & dosificación , Atención Primaria de Salud/métodos , SARS-CoV-2/genética , Cloruro de Sodio Dietético/administración & dosificación , Administración Oral , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Brasil/epidemiología , COVID-19/epidemiología , COVID-19/virología , Método Doble Ciego , Femenino , Estudios de Seguimiento , Homeopatía/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Resultado del Tratamiento , Adulto JovenRESUMEN
Homeopathy is widely used and broadly accepted by health care professionals and the general public but less in academic circles. To assess possible material health risks of homeopathic medicinal products, it is necessary to identify, select, and synthesize the findings of recent reviews of controlled homeopathic clinical trials. Matching these findings with experimental data from toxicological studies helps to clarify what is known and not known about the material risks of homeopathic medicines. Rules for toxicological risk assessment and management need to be applied independently of individual attitudes towards specific therapeutic options. European regulatory bodies have developed special protocols and decision trees to assure the safety of nonindividualized homeopathic remedies. This narrative review leads to suggestions that could ease and improve toxicological decision making. No homeopathy-specific type or pattern of side effects could be extracted from the meta-analysis data. No differences in the frequency of adverse reactions between homeopathic treatment and placebo treatment could be seen, no matter whether adverse events were reported in a quantitative or a qualitative manner. Some patterns of side effects show that adverse reactions do not necessarily correlate with treatment but with the condition of the patient. Overall, the controlled clinical data available for the material risk assessment of homeopathic remedies support the statement that, if a risk exists, it must be so small that it has not yet been established. To make our risk findings useful for personal decisions regarding homeopathy, we provide a thought experiment based on four different health situations and ask the question: is homeopathy as a monotherapy or as an add-on treatment an option or should it be rejected?
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Homeopatía , Materia Medica , Homeopatía/efectos adversos , Homeopatía/normas , Humanos , Materia Medica/efectos adversos , Materia Medica/normasRESUMEN
Regulatory agencies have to ensure the end-user safety of botanically derived homeopathic medicines prepared with diluted starting materials derived even from toxic plants. In the case of plant-derived homeopathic products, assessment must consider the particular characteristics of an extract and its component molecules, even if diluted. The identification and quantification of these molecules have a crucial role in risk assessment, as it allows complete toxicological evaluation in a regulatory perspective. Different results can be achieved using different approaches and references supported by the same regulatory framework, as different methods of preparation used, assays and test analysis performed in compliance with different referent pharmacopoeias. All these facts can introduce a bias in the safety assessment and the paradoxical outcome for homeopathic Adonis vernalis underlines the need for caution. The case also demonstrates the relevance of considering the analytical method for assessment of all herbal medicinal products or herbal supplements, with the purpose of finding the total amount of toxicants as a good approach.
Asunto(s)
Adonis/toxicidad , Homeopatía/efectos adversos , Farmacopeas Homeopáticas como Asunto , Fitoquímicos/toxicidad , Extractos Vegetales/toxicidad , Pruebas de Toxicidad , Animales , Seguridad de Productos para el Consumidor , Técnicas de Apoyo para la Decisión , Relación Dosis-Respuesta a Droga , Homeopatía/normas , Humanos , Farmacopeas Homeopáticas como Asunto/normas , Fitoquímicos/aislamiento & purificación , Fitoquímicos/normas , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/normas , Control de Calidad , Medición de RiesgoRESUMEN
Serotonin syndrome is due to excess serotonin in the nervous system. We document a case of an elderly Parkinson disease patient who has been neurologically stable on rasagiline and escitalopram for 1 year but developed serotonin syndrome after intake of an ethanol-containing homeopathic medication. The patient presented with seizures, autonomic dysfunction and neuromuscular hyperexcitability. Maintenance medications were discontinued, hydration, sedation and respiratory support were provided with resolution of the symptoms. The combination of escitalopram and ethanol, both metabolized by the cytochrome P450 enzyme system can lead to serotonin syndrome. Our case highlights the importance of drug interactions in patients taking several medications. Additionally, the intake of medicines, may it be conventional or homeopathic medicine, without the guidance of a trained and competent physician, may lead to serious consequences for the patient.
Asunto(s)
Citalopram/efectos adversos , Etanol/efectos adversos , Homeopatía/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/efectos adversos , Síndrome de la Serotonina/etiología , Anciano , Interacciones Farmacológicas , Femenino , Humanos , Indanos/uso terapéuticoAsunto(s)
Betacoronavirus , Protocolos Clínicos , Infecciones por Coronavirus/terapia , Homeopatía/métodos , Neumonía Viral/terapia , Medicina de Precisión/métodos , Discusiones Bioéticas , COVID-19 , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Combinación de Medicamentos , Homeopatía/efectos adversos , Homeopatía/normas , Humanos , Pandemias/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Medicina de Precisión/efectos adversos , SARS-CoV-2RESUMEN
The effects of infection with Toxoplasma gondii vary from asymptomatic to the development of alterations in various organs (including the liver and kidneys) which may be irreversible, and lead to the death of the host. Whereas homeopathy is an alternative and effective method for treating various diseases, including those caused by protozoa, we questioned the effect of using Lycopodium clavatum in mice infected with T. gondii. One hundred male Swiss mice, 60 days old, were divided into four groups (n = 25/group): NIC (uninfected and untreated control), IC (infected and treated with un-dynamized 7% alcohol solution [vehicle]), G48 (infected and treated 48 h before infection and treated three more times; at 2, 4, and 6 days post-infection (dpi) with L. clavatum 200dH), and G72 (infected and treated for 3 consecutive days before infection with L. clavatum 200dH). In this study, physiological, histopathological, and immunological parameters were evaluated. The L. clavatum 200dH intensified renal damage in mice infected with T. gondii from 7 dpi, causing severe and progressive alterations during this period, such as various degrees of inflammation, edema, atrophy, and tubular cystic dilation, degenerated tubules with intra-cytoplasmic vacuoles and coalescing spots, severe vascular lesions, glomerulonephritis, and peri-glomerular congestion. In the G72 animals, which received L. clavatum 200dH, more severe cortex damage was observed (91.66-96.66%) as compared to the IC group (55-80%) and more renal corpuscle, and renal tubule injury was observed (80 ± 5 to 96.7% ± 2.89 of the total area) during all periods, as compared to the IC group (p < 0.05). Both groups presented high liver enzyme levels, and the highest values for AST were observable at 60 dpi. We observed significant increases of type I and III collagen, as well as high levels of TGF-ß1 in both organs of the treated animals, the main factor involved in fibrosis in areas damaged by the process. L. clavatum 200dH intensifies kidney and liver alterations in mice infected with T. gondii. Our results reinforce caution when indicating administration schemes and dosages for ultra-diluted drugs.
Asunto(s)
Glomerulonefritis/patología , Hepatitis/patología , Homeopatía/efectos adversos , Lycopodium/efectos adversos , Toxoplasmosis/tratamiento farmacológico , Animales , Colágeno/metabolismo , Modelos Animales de Enfermedad , Fibrosis , Glomerulonefritis/metabolismo , Glomerulonefritis/parasitología , Hepatitis/metabolismo , Hepatitis/parasitología , Masculino , Ratones , Preparaciones de Plantas/efectos adversos , Toxoplasma/patogenicidad , Toxoplasmosis/patología , Factor de Crecimiento Transformador beta1/metabolismoAsunto(s)
Humanos , Neumonía Viral/terapia , Protocolos Clínicos , Infecciones por Coronavirus/terapia , Medicina de Precisión/métodos , Betacoronavirus , Homeopatía/métodos , Neumonía Viral/prevención & control , Neumonía Viral/epidemiología , Infecciones por Coronavirus , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/epidemiología , Discusiones Bioéticas , Combinación de Medicamentos , Medicina de Precisión/efectos adversos , Pandemias/prevención & control , Homeopatía/efectos adversos , Homeopatía/normasRESUMEN
RESUMO Introdução: A lesão central de células gigantes é própria dos ossos gnáticos, sendo um tumor benigno não odontogênico. É uma lesão de crescimento predominantemente lento, bem circunscrito e assintomático, geralmente diagnosticada através de algum exame de rotina ou, em casos mais avançados, quando se começa a visualizar alguma alteração estético-anatômica ou através da queixa do paciente de algum desconforto localizado na região. Objetivo: Ilustrar um caso clínico de lesão central de células gigantes e sua resolução envolvendo momento cirúrgico e reabordagem que inclui a homeopatia na proposta terapêutica. Apresentação do caso: Paciente do sexo feminino, inicialmente com 4 anos de idade com uma lesão na região de pré-maxila. Após avaliação radiográfica, tomográfica, exames sanguíneos e biópsia incisional, foi realizada, em primeiro momento, a exérese da lesão sob anestesia geral, por curetagem com aplicação de solução de carnoy. Após proservação e surgimento de imagem radiopaca nos exames, deu-se início ao tratamento não invasivo com homeopatia e injeções de corticoide visando à redução e neoformação óssea em área sugestiva de tecido cicatricial. Conclusões: Abordagens mais conservadoras podem ser, em muitos casos, uma opção plausível que acaba por livrar o paciente de cirurgias mutilantes(AU)
RESUMEN Introducción: La lesión central de células gigantes es propia de los huesos gnáticos, lo que constituye un tumor benigno no odontogénico. Es una lesión de crecimiento predominantemente lento, bien circunscrita y asintomática, generalmente diagnosticada a través de algún examen de rutina o en casos más avanzados cuando se empieza a visualizar alguna alteración estético-anatómica o el paciente que se queja de algún malestar localizado en la región. Objetivo: Presentar un caso clínico de lesión central de células gigantes y su resolución involucrando momento quirúrgico y reabordaje que incluye la homeopatía en la propuesta terapéutica. Presentación del caso: Paciente del sexo femenino, inicialmente con 4 años de edad con una lesión en la región de pre-maxila. Después de la evaluación radiográfica, tomográfica, exámenes sanguíneos y biópsia incisional con el diagnóstico, se realizó en un primer momento la exéresis de la lesión bajo anestesia general, por curetaje con aplicación de solución de carnoy. En los exámenes de acompañamiento, después de la aparición de imagen radiopaca, se inició el tratamiento no invasivo con homeopatía e inyecciones de corticoides para la reducción y neoformación ósea en el área sugestiva de tejido cicatricial. Conclusiones: Los enfoques más conservadores pueden ser, en muchos casos, una opción plausible que termina librando al paciente de cirugías de mutilación(AU)
ABSTRACT Introduction: Giant cell central lesion is characteristic of the gnathic bones, being a non-odontogenic benign tumor. Classified as a predominantly slow grotwh, well-circumscribed and asymptomatic lesion usually diagnosed through routine examination or in some and more advanced cases once it begins to create some aesthetic-anatomical alteration or when the patient starts complaining of some located discomfort in the region. Objective: To present a clinical case of central giant cell lesion and its resolution involving surgical approach and second management, which includes homeopathy as a therapeutic proposal. Case presentation: central giant cell lesion located in the premaxilla region in a 4 years old female patient. After radiographic, tomographic and blood exams evaluation, followed by incisional biopsy and diagnostic, leading to surgical approach to remove the entire lesion by curettage with Carnoy's solution application under general anesthesia. After appearance of radiopaque imaging in the proservation examinations, the non-invasive treatment by corticoid injection and homeopathy got started aiming the reduction of cicatricial tissue's suggestive area and neoformation of the bone. Conclusions : approaches that are more conservative can be, in many cases, a plausible option that ends up ridding the patient of mutilating surgeries(AU)
Asunto(s)
Humanos , Femenino , Preescolar , Enfermedades Maxilares/cirugía , Tumores de Células Gigantes/diagnóstico por imagen , Homeopatía/efectos adversosRESUMEN
OBJECTIVE: To compare the differences in the use of healthcare services: visits to the doctor and hospitalisation, performance of routine tests, and preventive influenza vaccination, between users and non-users of homeopathic products. METHODS: We used the microdata for adults over 15 years old from three waves of the Spanish National Health Survey, corresponding to the years 2011, 2014 and 2017. We proposed a comparative design of a quasi-experimental type, considering as the treatment group the respondents who said that they had used homeopathic products in the past two weeks; and another group, for control, comprising respondents who said that they had not used this type of products, but only conventional medicines, with observable characteristics similar to those of the treatment group. We used a model for rare events logistics regression (relogit) to estimate the probability of using homeopathy. From the propensity score and a vector of control variables, we used techniques of genetic matching to match individuals from the treatment group with similar individuals belonging to the control group. RESULTS: There are no statistically significant differences between users and non-users of homeopathy in visits to the general practitioner (P>|z| 0.387), to the specialist (P>|z| 0.52), in hospitalisations (P>|z| 0.592) or in the use of emergency services (P>|z| 0.109). Nor were there any statistically significant differences in the performance of routine tests, except for the faecal occult blood test, which is more prevalent in users of homeopathic products. 20.9% of users of homeopathy had done this test compared with 15.3% of non-users (P>|z| 0.022). There are also significant differences in vaccination against influenza with 12.6% of homeopathy users stating that they had been vaccinated in the last influenza campaign, against 21.0% of non-users (P>|z| <0.001). The health conditions which homeopathy users reported were constipation (OR: 1.65 CI: 1.16-2.36), malignant tumour (OR: 1.60 CI: 1.09-2.36) osteoporosis (OR: 1.49 CI: 1.05-2.10), varicose veins (OR: 1.35 CI: 1.05-1.74) and allergy (OR: 1.35 CI: 1.06-1.72). CONCLUSIONS: Differences in the use of healthcare resources between users and non-users of homeopathic products have not been found to be statistically significant in Spain. It has been shown that most homeopathic products are used as a complement to treatment with conventional medicine. Nevertheless, our results highlight some warning signs which should raise the attention of healthcare authorities. The use of these therapies in patients with malignant tumours and the rejection of vaccines are warning signs of a possible health hazard in the long term.
Asunto(s)
Atención a la Salud/tendencias , Homeopatía/psicología , Aceptación de la Atención de Salud/psicología , Adolescente , Adulto , Femenino , Encuestas Epidemiológicas , Homeopatía/efectos adversos , Humanos , Masculino , Materia Medica/efectos adversos , Persona de Mediana Edad , EspañaRESUMEN
We present a teetotaler with compensated non-alcoholic fatty-liver-disease related cirrhosis who presented with acute worsening of his chronic liver disease. The acute event was not discernible even after extensive work up and finally a transjugular liver biopsy revealed features suggestive of severe alcoholic hepatitis. The patient and the family denied occult alcohol use when questioned over multiple times and finally, the culprit 'alcohol' was found to be the homoeopathy medicines that the patient was consuming over a month for treatment of Gilbert's syndrome. We retrieved and tested the homoeopathy drug for alcohol content and found an alarming 18% ethanol in the same, confirming our diagnosis.